Equities analysts expect United Therapeutics Co. (NASDAQ:UTHR) to announce earnings per share (EPS) of $2.31 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $3.13 and the lowest estimate coming in at $1.88. United Therapeutics posted earnings per share of $3.98 in the same quarter last year, which suggests a negative year over year growth rate of 42%. The firm is expected to issue its next earnings report on Wednesday, October 30th.
According to Zacks, analysts expect that United Therapeutics will report full-year earnings of ($1.96) per share for the current fiscal year, with EPS estimates ranging from ($3.73) to ($0.50). For the next year, analysts expect that the business will report earnings of $9.36 per share, with EPS estimates ranging from $7.62 to $11.74. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for United Therapeutics.
A number of brokerages recently weighed in on UTHR. LADENBURG THALM/SH SH raised shares of United Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $103.00 to $106.00 in a report on Thursday, August 1st. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. Credit Suisse Group raised shares of United Therapeutics from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $98.00 to $101.00 in a report on Monday, July 1st. Jefferies Financial Group raised shares of United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 target price for the company in a report on Thursday, August 1st. Finally, ValuEngine raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $120.36.
In other news, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $395,250. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the transaction, the director now directly owns 3,750 shares in the company, valued at $285,412.50. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Pearl River Capital LLC bought a new position in shares of United Therapeutics during the second quarter worth $32,000. Private Ocean LLC bought a new position in shares of United Therapeutics during the second quarter worth $34,000. NEXT Financial Group Inc boosted its position in shares of United Therapeutics by 72.7% during the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 200 shares in the last quarter. Financial Gravity Wealth Inc. bought a new position in shares of United Therapeutics during the first quarter worth $46,000. Finally, Quadrant Capital Group LLC boosted its position in shares of United Therapeutics by 552.0% during the first quarter. Quadrant Capital Group LLC now owns 489 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 414 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: Quantitative Easing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.